Leal Therapeutics is focused on developing precision medicines aimed at addressing high-need central nervous system (CNS) disorders. The company has two lead programs: an antisense oligonucleotide (ASO) targeting lipid biology for both sporadic and genetic amyotrophic lateral sclerosis (ALS) patients, and an oral small molecule designed to target glutamate biology for schizophrenia. These lead programs are on track for Investigational New Drug (IND) applications this year, with clinical data expected to emerge in 2025. In addition to these, Leal Therapeutics has a robust pipeline that includes programs targeting Alzheimer’s disease, epilepsy, and depression, utilizing various modalities such as ASOs and small molecules.

The pipeline includes several specific programs: LTX-002, which targets SPTLC1 and lipid metabolism for ALS and peripheral neuropathy; LTX-001, which focuses on GLS1 and glutamate presynaptic mechanisms for schizophrenia and major depressive disorder (MDD); and LTX-003, targeting complement pathways for Alzheimer’s disease and frontotemporal dementia (FTD). Other programs include LTX-004, which addresses lipid trafficking in Alzheimer’s and dementia with Lewy bodies, and LTX-005, which targets glutamate NMDAR for refractory epilepsy and treatment-resistant depression (TRD). Through these innovative approaches, Leal Therapeutics aims to develop novel therapeutics that effectively target key pathogenic pathways in CNS disorders.

United States

Leal Therapeutics is a biopharmaceutical company that focuses on developing novel therapeutics for patients with major disorders of the central nervous system.

Leal Therapeutics

Company Details